Bicycle Therapeutics PLC
BCYC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001761612
In the last 90 days, Bicycle Therapeutics PLC insiders filed 0 open-market purchases and 5 sales; 103 institutions reported holding it in 13F filings for Q2 2026, worth $157.9M in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Bicycle Therapeutics PLC as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 97
- −7 vs. Q3 2024
- Shares held
- 41.9M
- +1.47M (+3.6%) vs. Q3 2024
- Total value
- $586.5M
- −$328.3M (−35.9%) vs. Q3 2024
- New holders
- 16
- 29 more added
- Sold out
- 23
- 36 more reduced
1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BCYC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 103 | $157.9M |
| Q1 2026 | 98 | $173.6M |
| Q4 2025 | 109 | $276.9M |
| Q3 2025 | 99 | $285.6M |
| Q2 2025 | 110 | $286.3M |
| Q1 2025 | 95 | $354.4M |
| Q4 2024 | 97 | $586.5M |
| Q3 2024 | 105 | $915.3M |
| Q2 2024 | 107 | $804.0M |
| Q1 2024 | 95 | $759.1M |
| Q4 2023 | 101 | $567.4M |
| Q3 2023 | 101 | $651.3M |
| Q2 2023 | 85 | $618.5M |
| Q1 2023 | 89 | $498.9M |
| Q4 2022 | 87 | $695.9M |
| Q3 2022 | 79 | $538.0M |
| Q2 2022 | 82 | $381.1M |
| Q1 2022 | 105 | $884.5M |
| Q4 2021 | 101 | $1.31B |
| Q3 2021 | 69 | $591.1M |
| Q2 2021 | 54 | $376.9M |
| Q1 2021 | 39 | $341.2M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Bicycle Therapeutics PLC; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Logos Global Management LP | 0 | $0 | 0.00% | −500,000−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −330,258−100.0% | Sold out |
| Kennedy Capital Management, Inc. | 0 | $0 | 0.00% | −261,067−100.0% | Sold out |
| Duquesne Family Office LLCSuperinvestorDuquesne Family Office | 0 | $0 | 0.00% | −190,200−100.0% | Sold out |
| Fairmount Funds Management LLC | 0 | $0 | 0.00% | −123,538−100.0% | Sold out |
| Granahan Investment Management Inc | 0 | $0 | 0.00% | −96,916−100.0% | Sold out |
| Soleus Capital Management, L.P. | 0 | $0 | 0.00% | −78,315−100.0% | Sold out |
| L & S Advisors Inc | 0 | $0 | 0.00% | −59,735−100.0% | Sold out |
| Gilder Gagnon Howe & Co LLC | 0 | $0 | 0.00% | −43,904−100.0% | Sold out |
| AlphaCentric Advisors LLC | 0 | $0 | 0.00% | −37,500−100.0% | Sold out |
| Davenport & Co LLC | 0 | $0 | 0.00% | −20,650−100.0% | Sold out |
| NEOS Investment Management LLC | 0 | $0 | 0.00% | −17,652−100.0% | Sold out |
| Nomura Holdings Inc | 0 | $0 | 0.00% | −13,095−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −11,600−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −11,300−100.0% | Sold out |
| Pathstone Holdings, LLC | 0 | $0 | 0.00% | −10,228−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −771−100.0% | Sold out |
| Macroview Investment Management LLC | 0 | $0 | 0.00% | −126−100.0% | Sold out |
| Clear Street Markets LLC | 0 | $0 | 0.00% | −97−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −30−100.0% | Sold out |
| PEAK6 Investments LLC | – | – | – | – | Not filed |